Home Newsfeeds INOVIO Says Phase 2 REVEAL2 Trial Evaluating VGX-3100 Did Not Meet Primary Endpoint

INOVIO Says Phase 2 REVEAL2 Trial Evaluating VGX-3100 Did Not Meet Primary Endpoint

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the primary endpoint in

byBenzinga Newsdesk

March 1, 2023

1 minute read

Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL)
- Trial results did not meet the primary endpoint in the biomarker-selected population
  - Trial results did achieve statistical significance in the all-participants population

Jefferies Maintains Hold on Cloudflare, Lowers Price Target to $60

By Benzinga Newsdesk

October 25, 10:35 AM

Jefferies analyst Brent Thill maintains Cloudflare (NYSE:NET) with a Hold and lowers the price target from $70 to $60.

NET

Bitcoin Surges Above $21K, Ethereum, Dogecoin Rally Intact — Analyst Says This ‘Could Awaken Some Dormant Long-Term Bulls’

By Mehab Qureshi

January 15, 10:50 PM

Major coins traded green on Sunday buoyed by renewed investor confidence that the Federal Reserve is managing inflation successfully without pushing the economy into recession.

$DOGE

AbbVie Announces Late-Breaking Results From Phase 2 Exploratory NOVA Trial Of Novel Investigational Neurotoxin AGN-151607 For The Prevention Of Postoperative Atrial Fibrillation In Cardiac Surgery Patients, Primary Endpoint Was Not Met

By Benzinga Newsdesk

November 7, 1:35 PM

Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients

ABBV

18 EV, Battery Startups Trying To Rival Tesla Likely To Run Out Of Cash Next Year: WSJ

By Benzinga Neuro

December 20, 5:51 AM

This includes high-profile companies like Nikola and Fisker, which previously garnered substantial investor attention with their ambitious industry-transforming plans.

FSR

INOVIO Says Phase 2 REVEAL2 Trial Evaluating VGX-3100 Did Not Meet Primary Endpoint

Related Posts

Jefferies Maintains Hold on Cloudflare, Lowers Price Target to $60

Bitcoin Surges Above $21K, Ethereum, Dogecoin Rally Intact — Analyst Says This ‘Could Awaken Some Dormant Long-Term Bulls’

AbbVie Announces Late-Breaking Results From Phase 2 Exploratory NOVA Trial Of Novel Investigational Neurotoxin AGN-151607 For The Prevention Of Postoperative Atrial Fibrillation In Cardiac Surgery Patients, Primary Endpoint Was Not Met

18 EV, Battery Startups Trying To Rival Tesla Likely To Run Out Of Cash Next Year: WSJ